Roche Holding AG Participation (ROGN)

7,963.170
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    7,700.000/7,999.000
  • Day's Range:
    7,963.170 - 7,963.170
  • Type:Equity
  • Market:Mexico
  • ISIN:CH0012032048

ROGN Overview

Prev. Close
8,059.33
Day's Range
7,963.17-7,963.17
Revenue
1.32T
Open
7,963.17
52 wk Range
6,616-8,200.27
EPS
-
Volume
0
Market Cap
6.73T
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,027
P/E Ratio
-
Beta
-
1-Year Change
11.27%
Shares Outstanding
854,260,903
Next Earnings Date
-
What is your sentiment on Roche Holding AG Participation?
or
Market is currently closed. Voting is open during market hours.

Roche Holding AG Participation News

  • Roche Holding reports FY results
    • BySeeking Alpha-

    Roche Holding (OTCQX:RHHBY): FY Non-GAAP EPS of CHF19.16; GAAP EPS of CHF16.52.Revenue of CHF58.32B (-5.1% Y/Y)Board proposes dividend to increase to CHF 9.10.Outlook for 2021:...

Roche Holding AG Participation Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyBuyStrong Buy
Technical IndicatorsNeutralSellBuyStrong BuyStrong Buy
SummaryNeutralNeutralBuyStrong BuyStrong Buy

Roche Holding AG Participation Company Profile

Roche Holding AG Participation Company Profile

Employees
101465

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Read More
  • A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
    3
    • Trades ex dividend!!
      0
      • Currently near to Fibo 61.8 levels, a great company to buy IMO.
        0
        • Any comments?
          0
          • Still holding, not a good stock tho..
            2
        • cant make it even during pandemic, sell
          2
          • I've invested in Roche.VX, is it the right stock?
            0
            • Which one is the real Roche stock? I found out today that a big company in Germany is buying covid tests from Roche but i don't know for sure in which stock should i invest.  The stock will go surely up but i wanna be in the right one. I've invested in this one but i am not sure if it's the real one because i heard a rumour and they said that the tests are coming from FRANCE. If someone can help me understand, thank you.
              4
              • CH:ROG
                0
              • nevertheess, i would buy below 300. its probably gonna test there. roche is not perfoming at its best at the moment. when buy now the longterm ... because dividends are pretty good here. if you hold 20 years - the dividends would have paid you back the amount you spend now
                0
              • france = Sanofi is not Roche
                0
            • Roche : Rolls Out Coronavirus Antibody Test https://www.marketscreener.com/ROCHE-HOLDING-AG-9364975/news/Roche-Rolls-Out-Coronavirus-Antibody-Test-30637349/
              0
              • What is the different between RHHBY and RHHVF?
                0
                • This is presentaion for Q1 https://www.roche.com/dam/jcr:e489e27b-f777-4781-b112-70c0bbfc4bdf/en/irp200422-a.pdf
                  5
                  • im buying, this is going to be 600-700 this year
                    0
                    • Great solid Q1 Results and some nice info about Covid-19 Diagnosis Machines..
                      0
                      • is it now too late to buy more ?
                        1
                        • noup, this will go up much more
                          0
                      • Yall tripping i have 2 companies im investing in and this is one of them. They are gonna supply americans and maybe the world with test kits for the virus. This alone will bring their price up.
                        0
                        • Do the Swiss not know Roche Covid-19 tests have been FDA approved? How is this dropping guys?
                          0
                          • Exactly im about to aggressively put 30% of my portfolio on this stock. I believe price may even more then double in the coming months to years.
                            0
                        • Long term.
                          0
                          • Turkish bank YAPI KREDI #ykbnk target 1,5 $
                            2
                            • Buy this stock @190, it's very good for long term..
                              1
                              • agreed... around 180/190 it will look ok.
                                0
                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.